FATE

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.

Wall Street analysts forecast FATE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FATE is 5.29 USD with a low forecast of 2.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fate Therapeutics Inc revenue for the last quarter amounts to 1.74M USD, decreased -43.36 % YoY.

Fate Therapeutics Inc. EPS for the last quarter amounts to -0.27 USD, decreased -32.50 % YoY.

Fate Therapeutics Inc (FATE) has 181 emplpoyees as of December 15 2025.

Today FATE has the market capitalization of 132.66M USD.